Close X
Friday, November 1, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

Pipeline politics back before Commons committee

Pipeline politics back before Commons committee
Michigan has refused to concede that the state's own experts have concluded there are no clear alternatives to the pipeline, he wrote to the governor in a letter earlier this year.

Pipeline politics back before Commons committee

Minister defends attack petition on Bigfoot movie

Minister defends attack petition on Bigfoot movie
Sonya Savage also says it’s critical to push back constantly against any false narrative that casts Alberta’s wellspring industry in a negative light.

Minister defends attack petition on Bigfoot movie

Surrey Vaisakhi parade cancelled for 2021 due to COVID19

Surrey Vaisakhi parade cancelled for 2021 due to COVID19
The event was to take place in Surrey on April 24th. The Surrey Vaisakhi parade is the largest in Canada and outside of India drawing crowds in excess of over half a million. 

Surrey Vaisakhi parade cancelled for 2021 due to COVID19

Wanted: Ideas to prepare for next major calamity

Wanted: Ideas to prepare for next major calamity
The notice says these fall somewhere between relatively common events such as seasonal floods and highly improbably risks such as an asteroid hitting Earth.

Wanted: Ideas to prepare for next major calamity

O'Toole says he wouldn't cut foreign aid

O'Toole says he wouldn't cut foreign aid
O'Toole says a Conservative government also wouldn't cut aid funding, but would place a greater focus on measuring outcomes associated with that money.

O'Toole says he wouldn't cut foreign aid

AstraZeneca vaccine OK for seniors: NACI

AstraZeneca vaccine OK for seniors: NACI
The decision reverses a recommendation made by the body two weeks ago when the panel of vaccine experts said AstraZeneca hadn't included enough people over the age of 65 in its clinical trials.

AstraZeneca vaccine OK for seniors: NACI